Search

Displaying results 3791 - 3800 of 10000 in total
  1. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis. … CDP323 is an antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple

    Categories: Heterocyclic Compounds, 2-Ring
  2. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. … CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far.

  3. Drug

    Davamotecan pegadexamer

    go.drugbank.com/drugs/DB05899
    Investigational

    EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound [camptothecin].

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Mevastatin

    go.drugbank.com/drugs/DB06693
    Experimental

    Mevastatin or compactin is a cholesterol-lowering agent isolated from <i>Penicillium citinium</i>. … Mevastatin is a pro-drug that is activated by <i>in vivo</i> hydrolysis of the lactone ring. It has served as one of the lead compounds for the development of the synthetic compounds used today.

  5. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

  6. Drug

    Tezampanel

    go.drugbank.com/drugs/DB06354
    Investigational

    Tezampanel is an AMPA receptor antagonist.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  7. Drug

    Teverelix

    go.drugbank.com/drugs/DB05624
    Investigational

    A synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.

  8. Drug

    Contusugene ladenovec

    go.drugbank.com/drugs/DB05322
    Investigational

    INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. … Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.

  9. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    RP01 is a novel anti-IgE immunotherapy for allergic individuals. … It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response.

  10. Drug

    DOTMP HO-166

    go.drugbank.com/drugs/DB05380
    Experimental

    SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in … It is an experimental therapy that is being developed by NeoRx Corporation.